OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 subvariant predominance: a systematic literature review
Myriam Drysdale, Daniel C. Gibbons, Moushmi Singh, et al.
Infection (2023) Vol. 52, Iss. 1, pp. 1-17
Open Access | Times Cited: 10
Myriam Drysdale, Daniel C. Gibbons, Moushmi Singh, et al.
Infection (2023) Vol. 52, Iss. 1, pp. 1-17
Open Access | Times Cited: 10
Showing 10 citing articles:
COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 12
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 12
Real-World Effectiveness of Sotrovimab in Ambulatory Patients With COVID-19: A Retrospective Cohort Study Using a Large Administrative Claims Database in the United States
Christopher F. Bell, Tasneem Lokhandwala, Daniel C. Gibbons, et al.
Clinical Therapeutics (2025)
Open Access | Times Cited: 1
Christopher F. Bell, Tasneem Lokhandwala, Daniel C. Gibbons, et al.
Clinical Therapeutics (2025)
Open Access | Times Cited: 1
Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 and BA.5 subvariant predominance: a systematic literature review
Myriam Drysdale, Mehmet Berktaş, Daniel C. Gibbons, et al.
Infection (2024) Vol. 52, Iss. 5, pp. 1839-1861
Open Access | Times Cited: 5
Myriam Drysdale, Mehmet Berktaş, Daniel C. Gibbons, et al.
Infection (2024) Vol. 52, Iss. 5, pp. 1839-1861
Open Access | Times Cited: 5
60-day mortality and the role of SARS-CoV-2 in hospital admissions of immunocompromised patients during later Omicron period: a population-based study in Sweden
Armin Sprečo, Christer Andersson, Rune Sjödahl, et al.
Infectious Diseases (2025), pp. 1-13
Open Access
Armin Sprečo, Christer Andersson, Rune Sjödahl, et al.
Infectious Diseases (2025), pp. 1-13
Open Access
Impact of treatment of COVID-19 with sotrovimab on post-acute sequelae of COVID-19 (PASC): an analysis of National COVID Cohort Collaborative (N3C) data
Myriam Gharbi, Rose Chang, Tracy Guo, et al.
Infection (2025)
Open Access
Myriam Gharbi, Rose Chang, Tracy Guo, et al.
Infection (2025)
Open Access
Comparative effectiveness of sotrovimab versus no treatment in non-hospitalised high-risk COVID-19 patients in north west London: a retrospective cohort study
Myriam Drysdale, Evgeniy R. Galimov, Marcus J. Yarwood, et al.
BMJ Open Respiratory Research (2024) Vol. 11, Iss. 1, pp. e002238-e002238
Open Access | Times Cited: 2
Myriam Drysdale, Evgeniy R. Galimov, Marcus J. Yarwood, et al.
BMJ Open Respiratory Research (2024) Vol. 11, Iss. 1, pp. e002238-e002238
Open Access | Times Cited: 2
Lessons learnt from broad-spectrum coronavirus antiviral drug discovery
Andrew A. Bolinger, Jun Li, Xuping Xie, et al.
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 9, pp. 1023-1041
Closed Access | Times Cited: 1
Andrew A. Bolinger, Jun Li, Xuping Xie, et al.
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 9, pp. 1023-1041
Closed Access | Times Cited: 1
Monoclonal Antibody Therapies Against SARS-CoV-2: Promises and Realities
Daniele Focosi
Current topics in microbiology and immunology (2024)
Closed Access | Times Cited: 1
Daniele Focosi
Current topics in microbiology and immunology (2024)
Closed Access | Times Cited: 1
Sotrovimab lost neutralization efficacy against SARS-CoV-2 subvariants but remained clinically effective: Were monoclonal antibodies against COVID-19 rejected too early?
Line Lundegaard Bang, Lone Wulff Madsen, Rune M. Pedersen, et al.
Journal of Infection and Public Health (2024) Vol. 17, Iss. 9, pp. 102512-102512
Open Access
Line Lundegaard Bang, Lone Wulff Madsen, Rune M. Pedersen, et al.
Journal of Infection and Public Health (2024) Vol. 17, Iss. 9, pp. 102512-102512
Open Access
Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 and BA.5 subvariant predominance: a systematic literature review
Myriam Drysdale, Mehmet Berktaş, Daniel C. Gibbons, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1
Myriam Drysdale, Mehmet Berktaş, Daniel C. Gibbons, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1
